Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR 25 167

Opportunity Information: Apply for PAR 25 167

The Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required), funding opportunity number PAR 25-167, is a National Institutes of Health (NIH) grant run through the National Cancer Institute (NCI). Its purpose is to fund investigator-initiated clinical trials that can meaningfully reduce the overall burden of cancer by improving how cancer is prevented, detected early, and managed across the continuum of care. The program emphasizes research that can lead to real-world improvements in clinical practice and/or public health, rather than studies that are primarily exploratory without a clear path to impact.

The clinical focus is specifically on cancer prevention and control topics. Examples of the kinds of areas the NOFO is designed to support include early detection and screening approaches, prevention strategies (including interception, meaning intervening during early biological changes before invasive cancer develops), improvements in healthcare delivery related to cancer, and interventions that enhance quality of life and survivorship outcomes. The intended scope aligns with the interests of the NCI Division of Cancer Prevention and the NCI Division of Cancer Control and Population Sciences, signaling that projects should fit within prevention, population science, implementation, behavioral, outcomes, and care delivery domains tied to cancer.

A key requirement is that applications must propose a study that meets the NIH definition of a clinical trial and must include the specific clinical trial information required by the funding announcement. In other words, this is not an optional clinical trial mechanism; the project is expected to be a true clinical trial as NIH defines it, with appropriate trial-specific details provided in the application.

At the same time, the NOFO is explicit about what it will not support: it does not fund clinical trials focused on cancer diagnosis and/or oncologic therapy in patients. That exclusion is important because it differentiates this program from treatment-oriented trial funding. Applicants proposing trials of therapeutic regimens, treatment combinations, or other oncology treatment studies in patients would fall outside the allowable scope for this opportunity.

The funding instrument is an NIH R01 research project grant, categorized as a discretionary grant, and it falls under the Education and Health activity category. The associated CFDA numbers listed are 93.393 and 93.399. The opportunity was created on 2024-11-12, and the original closing date provided is 2027-01-07. An award ceiling and expected number of awards are not specified in the supplied source data.

Eligibility is broad and includes many types of domestic organizations and some non-domestic entities. Eligible applicants include state, county, city or township governments, special district governments, and independent school districts, as well as public and state-controlled institutions of higher education and private institutions of higher education. Tribal eligibility includes Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments), along with Indian housing authorities. Nonprofit organizations may apply whether or not they have 501(c)(3) status (so long as they are not institutions of higher education under that category), and for-profit organizations are also eligible (other than small businesses, with small businesses separately listed as eligible). The NOFO also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations.

Overall, this opportunity is best suited for investigators ready to run a well-defined clinical trial aimed at preventing cancer, improving screening/early detection, strengthening cancer-related healthcare delivery, or improving survivorship and quality of life outcomes, with a clear rationale for how the results could change practice or improve population health, while staying away from trials centered on diagnostic workups or cancer treatment in patients.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
• This funding opportunity was created on 2024-11-12.
• Applicants must submit their applications by 2027-01-07.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 25 167

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: